SGFG
ORIC icon

Silver Grove Financial Group’s Oric Pharmaceuticals ORIC Stock Holding History

Silver Grove Financial Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38K Buy
+127
New +$1.15K ﹤0.01% 1753

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silver Grove Financial Group's ORIC Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Oric Pharmaceuticals (ORIC) in Q2 2026: 127 shares worth $1.38K. The stake represents ﹤0.01% of the portfolio and ranks #1753 among its holdings.

180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Silver Grove Financial Group held 127 shares of Oric Pharmaceuticals worth $1.38K as of Q2 2026.
  • Oric Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1753 holding.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.